Physician profile
Robin Lifton
NPI 1437140068
$3,127.28
in general payments reported to CMS, 2019-2025
39 companies · $49.76 in 2025
The $49.76 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $485 · 2021: $406 · 2022: $824 · 2025: $49.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $235.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $228.55 | 2019-2020 | |
| Exelixis INC. | $222.09 | 2019-2021 | |
| Pfizer INC. | $195.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $194.27 | 2019-2022 | |
| Celgene Corporation | $159.36 | 2019-2022 | |
| Beigene USA, INC. | $148.75 | 2022 | |
| Amgen INC. | $140.51 | 2019-2022 | |
| Astellas Pharma US INC | $135.30 | 2019-2020 | |
| Genzyme Corporation | $132.84 | 2019-2025 | |
| Incyte Corporation | $124.70 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $120.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $109.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $93.52 | 2019-2021 | |
| Genentech USA, INC. | $91.56 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $87.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.96 | 2019-2020 | |
| Daiichi Sankyo INC. | $66.38 | 2019-2022 | |
| Lilly USA, LLC | $66.02 | 2019 | |
| Abbvie INC. | $57.58 | 2019-2022 | |
| Seagen INC. | $48.59 | 2019-2021 | |
| Gilead Sciences, INC. | $45.09 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.74 | 2020-2022 | |
| Taiho Oncology, INC. | $23.49 | 2019 | |
| Deciphera Pharmaceuticals INC. | $23.12 | 2022 | |
| Rigel Pharmaceuticals, INC. | $22.82 | 2019-2020 | |
| Eusa Pharma (US) LLC | $20.69 | 2022 | |
| Karyopharm Therapeutics INC. | $20.67 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.54 | 2020 | |
| Eisai INC. | $20.14 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2019 | |
| Kite Pharma, INC. | $15.62 | 2022 | |
| Array Biopharma INC | $15.00 | 2020 | |
| Partner Therapeutics, INC. | $14.60 | 2019 | |
| Tersera Therapeutics LLC | $13.73 | 2019 | |
| Aveo Pharmaceuticals, INC. | $13.65 | 2021 | |
| Emd Serono, INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lifton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.